WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsThomas Higgins - Senior VP, CFO & TreasurerShai Gozani - Founder,…

NeuroMetrix press release (NURO): Q4 GAAP EPS of -$0.09.Revenue of $1.84M (+1.1% Y/Y).Gross profit in Q4 2022 was $1.2 million, a decrease of 1.0% from the fourth quarter of 2021

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.

As of Wednesday, NeuroMetrix Inc.’s (NASDAQ:NURO) stock closed at $2.00, up from $1.91 the previous day. While NeuroMetrix Inc. has overperformed by 4.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NURO fell by -56.83%, with highs and lows ranging from $5.89 to $1.33, whereas the […]